Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on June 8, 2009

Hypertension. 2009
Published online before print June 8, 2009, doi: 10.1161/HYPERTENSIONAHA.109.133249
A more recent version of this article appeared on August 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
54/2/302    most recent
HYPERTENSIONAHA.109.133249v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Capone, C.
Right arrow Articles by Iadecola, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Capone, C.
Right arrow Articles by Iadecola, C.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Cerebrovascular disease/stroke
Right arrow Hypertension - basic studies
Right arrow Endothelium/vascular type/nitric oxide

Submitted on March 25, 2009
Revised on April 11, 2009

Estrous Cycle–Dependent Neurovascular Dysfunction Induced by Angiotensin II in the Mouse Neocortex

Carmen Capone; Josef Anrather; Teresa A. Milner; and Costantino Iadecola*

From the Division of Neurobiology (C.C., J.A., T.A.M., C.I.), Department of Neurology and Neuroscience, Weill Cornell Medical College; and Harold and Margaret Milliken Hatch Laboratory of Neuroendocrinology (T.A.M.), Rockefeller University, New York, NY.

* To whom correspondence should be addressed. E-mail: coi2001{at}med.cornell.edu.

Abstract—Female mice are protected from the cerebrovascular dysfunction induced by angiotensin II (Ang II), an effect attributed to estrogen. We examined whether such cerebrovascular protection from Ang II is related to the estrous cycle. Cerebral blood flow was monitored by laser-Doppler flowmetry in anesthetized (urethane-chloralose) C57BL/6 female mice equipped with a cranial window. The phase of the estrous cycle was determined by vaginal smear cytology and plasma estrogen measurement. Ang II (0.25 µg/kg per minute, IV, 30 to 45 minutes) elevated arterial pressure (15 to 20 mm Hg) equally across the estrous cycle. However, in proestrus and estrus, phases in which estrogen is relatively high, Ang II did not impair the increase in the cerebral blood flow induced by neural activity or by endothelium-dependent vasodilators (P>0.05 from vehicle). In contrast, in diestrus (lower estrogen), Ang II induced a marked cerebrovascular dysfunction comparable to that of male mice. For example, the cerebral blood flow responses to whisker stimulation and to the endothelium-dependent vasodilator acetylcholine were attenuated by 41±12% and 49±12%, respectively (P<0.05; n=6 per group). The protection from the cerebrovascular effects of Ang II in proestrus was abolished by the estrogen receptor inhibitor ICI182,780. Ang II also increased production of free radicals in cerebral blood vessels in diestrus (+116±13%; P<0.05) but not in proestrus and estrus (P>0.05 from control). Topical treatment with ICI182,780 reestablished Ang II–induced oxidative stress in proestrus (P>0.05 from diestrus). We conclude that the protection from the neurovascular dysfunction induced by acute administration of Ang II in females depends on the estrous cycle and may underlie the increased propensity to cerebrovascular damage associated with low estrogen states.


Key words: functional hyperemia • endothelium-dependent relaxation • sex differences • reactive oxygen species • laser-Doppler flowmetry